Evidence map›Paper›PMID 34258232›Full record

ArticleUrology case reports2021

Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors.

Jean-Michel Lavoie, Gillian Vandekerkhove, Andrew J Murtha, Gang Wang, Alexander W Wyatt, Bernhard J Eigl

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jean-Michel LavoieDepartment of Medical Oncology, BC Cancer - Surrey, Surrey, Canada.
Gillian VandekerkhoveVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
Andrew J MurthaVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
Gang WangDepartment of Pathology and Laboratory Medicine, BC Cancer - Vancouver, Vancouver, Canada.
Alexander W WyattVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
Bernhard J EiglDepartment of Medical Oncology, BC Cancer - Vancouver, Vancouver, Canada.
University of British Columbia · CABC Cancer Agency · CASurrey Memorial Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The management of metastatic urothelial cancer is rapidly evolving since immune checkpoint inhibitors were introduced. We present the case of a patient with metastatic upper tract urothelial cancer who had a complete response to durvalumab and tremelimumab. This patient then developed multiple non-invasive papillary bladder tumours. Next-generation sequencing revealed that the tumours shared ancestry with the upper tract cancer, although there were key differences, most notably the presence of a

Indexed as

Checkpoint inhibitorNext-generation sequencingUrothelial cancer

Identifiers

PMID34258232
PMCPMC8254020
OpenAlexW3174459433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.